A Safety Study of SGN-CD19A for B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

February 16, 2017

Conditions
Burkitt LymphomaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellPrecursor B-cell Lymphoblastic Leukemia-Lymphoma
Interventions
DRUG

SGN-CD19A

SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)

Trial Locations (6)

10021

Memorial Sloan Kettering Cancer Center, New York

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

35294

University of Alabama at Birmingham, Birmingham

94305

Stanford Cancer Center, Stanford

91010-3000

City of Hope National Medical Center, Duarte

77030-4095

MD Anderson Cancer Center / University of Texas, Houston

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT01786135 - A Safety Study of SGN-CD19A for B-Cell Lymphoma | Biotech Hunter | Biotech Hunter